Holen Sie sich die Stockscreener-App
1.68
6.67%
-0.12
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
Bank of America Corp DE Sells 7,001 Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Brokers Set Expectations for ARTV Q2 Earnings - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded by HC Wainwright to Buy Rating - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at HC Wainwright - Defense World
Brokers Offer Predictions for ARTV FY2026 Earnings - Defense World
Promising Advancements and Financial Strength Position Artiva Biotherapeutics for Significant Upside - TipRanks
Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright - TipRanks
NK Cell Therapy Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
Deutsche Bank AG Takes Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Shares Bought by BNP Paribas Financial Markets - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Analysts - Defense World
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Reviewing Bio-Techne (NASDAQ:TECH) and Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price - Defense World
Research Analysts Offer Predictions for ARTV FY2025 Earnings - Defense World
Artiva Biotherapeutics Reports Q1 2025 Progress - MSN
Artiva Biotherapeutics announces new, long-term data for AlloNK combination - TipRanks
Artiva Biotherapeutics Reports Promising Phase 1/2 Data for AlloNK® in Combination with Rituximab for Heavily Pretreated B-cell Non-Hodgkin Lymphoma Patients - Nasdaq
Artiva reports promising AlloNK therapy results in B-NHL study - Investing.com
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewswire
Artiva Biotherapeutics, Inc. Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK®? in Combination with Rituximab in Patients with B-Cell-Cell- Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - marketscreener.com
Artiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating - TipRanks
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance - TipRanks
Artiva Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Acquires 26,893 Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Shares Acquired by Geode Capital Management LLC - Defense World
Artiva Biotherapeutics Announces Promising Data for AlloNK® + Rituximab in B-cell Driven Diseases Ahead of ASGCT 28th Annual Meeting - Nasdaq
Artiva Biotherapeutics to Present Longer-term Phase 1/2 - GlobeNewswire
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - Yahoo Finance
NK Cell Therapy Therapeutics Market Size in 7MM is expected - openPR.com
Norges Bank Buys New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Norges Bank Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - The AM Reporter
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support - TipRanks
Artiva Biotherapeutics names new Chief Medical Officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Names New Chief Medical Officer - marketscreener.com
Artiva Biotherapeutics names new Chief Medical Officer - Investing.com Australia
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday SessionAgilon Health (NYSE:AGL), Alumis (NASDAQ:ALMS) - Benzinga
Artiva Biotherapeutics (ARTV) – Investment Analysts’ Recent Ratings Changes - Defense World
12 Health Care Stocks Moving In Monday's Intraday SessionAditxt (NASDAQ:ADTX), Alumis (NASDAQ:ALMS) - Benzinga
Artiva Biotherapeutics Reports 2024 Financial Results - TipRanks
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year - Investing.com Canada
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year By Investing.com - Investing.com South Africa
2.13%
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):